JP2025060958A5 - - Google Patents

Info

Publication number
JP2025060958A5
JP2025060958A5 JP2024232254A JP2024232254A JP2025060958A5 JP 2025060958 A5 JP2025060958 A5 JP 2025060958A5 JP 2024232254 A JP2024232254 A JP 2024232254A JP 2024232254 A JP2024232254 A JP 2024232254A JP 2025060958 A5 JP2025060958 A5 JP 2025060958A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
integrin
rnai agent
targeting ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024232254A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025060958A (ja
Filing date
Publication date
Priority claimed from PCT/US2019/029393 external-priority patent/WO2019210200A1/en
Application filed filed Critical
Publication of JP2025060958A publication Critical patent/JP2025060958A/ja
Publication of JP2025060958A5 publication Critical patent/JP2025060958A5/ja
Pending legal-status Critical Current

Links

JP2024232254A 2018-04-27 2024-12-27 インテグリン標的化リガンドとその使用 Pending JP2025060958A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862663763P 2018-04-27 2018-04-27
US62/663,763 2018-04-27
US201962790372P 2019-01-09 2019-01-09
US62/790,372 2019-01-09
PCT/US2019/029393 WO2019210200A1 (en) 2018-04-27 2019-04-26 Integrin targeting ligands and uses thereof
JP2020560257A JP7704529B2 (ja) 2018-04-27 2019-04-26 インテグリン標的化リガンドとその使用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020560257A Division JP7704529B2 (ja) 2018-04-27 2019-04-26 インテグリン標的化リガンドとその使用

Publications (2)

Publication Number Publication Date
JP2025060958A JP2025060958A (ja) 2025-04-10
JP2025060958A5 true JP2025060958A5 (cg-RX-API-DMAC10.html) 2025-10-08

Family

ID=68294255

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020560257A Active JP7704529B2 (ja) 2018-04-27 2019-04-26 インテグリン標的化リガンドとその使用
JP2024232254A Pending JP2025060958A (ja) 2018-04-27 2024-12-27 インテグリン標的化リガンドとその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020560257A Active JP7704529B2 (ja) 2018-04-27 2019-04-26 インテグリン標的化リガンドとその使用

Country Status (20)

Country Link
US (1) US12667619B2 (cg-RX-API-DMAC10.html)
EP (2) EP4435000A3 (cg-RX-API-DMAC10.html)
JP (2) JP7704529B2 (cg-RX-API-DMAC10.html)
KR (1) KR102787533B1 (cg-RX-API-DMAC10.html)
CN (2) CN112074290B (cg-RX-API-DMAC10.html)
AU (1) AU2019260738B2 (cg-RX-API-DMAC10.html)
BR (1) BR112020021949A2 (cg-RX-API-DMAC10.html)
CA (1) CA3097656A1 (cg-RX-API-DMAC10.html)
DK (1) DK3784269T3 (cg-RX-API-DMAC10.html)
ES (1) ES2983950T3 (cg-RX-API-DMAC10.html)
FI (1) FI3784269T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20240907T1 (cg-RX-API-DMAC10.html)
IL (2) IL309955A (cg-RX-API-DMAC10.html)
JO (1) JOP20200266A1 (cg-RX-API-DMAC10.html)
MX (1) MX2020011290A (cg-RX-API-DMAC10.html)
SA (1) SA520420426B1 (cg-RX-API-DMAC10.html)
SG (1) SG11202009734VA (cg-RX-API-DMAC10.html)
SI (1) SI3784269T1 (cg-RX-API-DMAC10.html)
TW (1) TW202014206A (cg-RX-API-DMAC10.html)
WO (1) WO2019210200A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL309955A (en) 2018-04-27 2024-03-01 Arrowhead Pharmaceuticals Inc Integrin-targeting ligands and their uses
KR20210113273A (ko) 2019-01-09 2021-09-15 애로우헤드 파마슈티컬스 인코포레이티드 HIF-2 알파 (EPAS1)의 발현을 억제하기 위한 RNAi 작용제, 그의 조성물, 및 사용 방법
AU2021342155A1 (en) * 2020-09-11 2023-04-13 Arrowhead Pharmaceuticals, Inc. RNAi agents for inhibiting expression of DUX4, compositions thereof, and methods of use
EP4367246A4 (en) * 2021-07-07 2026-07-29 Alnylam Pharmaceuticals Inc Integrin-targeting ligands for the ocular administration of arni compounds
CN121399119A (zh) * 2023-06-19 2026-01-23 广东众生睿创生物科技有限公司 一种整合素配体及其用途
WO2025252118A1 (zh) * 2024-06-06 2025-12-11 苏州瑞博生物技术股份有限公司 整联蛋白αvβ6特异性配体化合物、缀合物、药物组合物及其用途
WO2025261536A1 (zh) * 2024-06-21 2025-12-26 长春金赛药业有限责任公司 一种整联蛋白配体关键中间体及其制备方法
WO2026034639A1 (ja) * 2024-08-09 2026-02-12 株式会社Spin Wave ペプチド合成用可溶性担体およびこれを用いた合成方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US6048861A (en) * 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
US6017926A (en) * 1997-12-17 2000-01-25 Merck & Co., Inc. Integrin receptor antagonists
SK9192000A3 (en) * 1997-12-17 2001-03-12 Merck & Co Inc Integrin receptor antagonists
AU2002337954C1 (en) 2001-10-22 2008-10-23 The Scripps Research Institute Integrin targeting compounds
US20040224986A1 (en) * 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
EP2990410A1 (en) 2004-08-10 2016-03-02 Alnylam Pharmaceuticals Inc. Chemically modified oligonucleotides
EP3673922A1 (en) * 2008-03-14 2020-07-01 VisEn Medical, Inc. Integrin targeting agents and methods of using same
JP2012517447A (ja) 2009-02-10 2012-08-02 ザ スクリプス リサーチ インスティチュート 化学的にプログラムされたワクチン接種法
US9586916B2 (en) * 2012-01-27 2017-03-07 Hoffmann-La Roche Inc. Integrin antagonist conjugates for targeted delivery to cells expressing alpha-V-beta-3
JP6383735B2 (ja) 2013-01-28 2018-08-29 ヤンセン・サイエンシズ・アイルランド・ユーシー Rsウイルスの抗ウイルス剤としてのキノキサリノンおよびジヒドロキノキサリノン
HK1214301A1 (zh) * 2013-02-28 2016-07-22 箭头研究公司 治療epas1相關疾病的有機組合物
WO2015021092A1 (en) 2013-08-07 2015-02-12 Arrowhead Research Corporation Polyconjugates for delivery of rnai triggers to tumor cells in vivo
EP3925959A1 (en) * 2015-02-19 2021-12-22 OcuTerra Therapeutics, Inc. Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof
EP3273965A4 (en) 2015-03-26 2018-12-05 Merck Sharp & Dohme Corp. Composition and methods for treating chronic kidney disease
US11971402B2 (en) 2015-04-24 2024-04-30 Cornell University Methods and reagents for determination and treatment of organotropic metastasis
JP2018514568A (ja) * 2015-04-30 2018-06-07 サイフルーア ライフ サイエンシズ インコーポレイテッド テトラヒドロナフチリジニルプロピオン酸誘導体およびその使用法
TWI761305B (zh) 2015-05-29 2022-04-21 美商愛羅海德製藥公司 抑制Hif2α基因表現之組合物及方法
CN120247964A (zh) 2018-02-17 2025-07-04 箭头药业股份有限公司 三炔连接剂和使用方法
IL309955A (en) * 2018-04-27 2024-03-01 Arrowhead Pharmaceuticals Inc Integrin-targeting ligands and their uses

Similar Documents

Publication Publication Date Title
JP2025094100A5 (cg-RX-API-DMAC10.html)
JP2021530451A5 (cg-RX-API-DMAC10.html)
JP2008540649A5 (cg-RX-API-DMAC10.html)
JP2003509401A5 (cg-RX-API-DMAC10.html)
JP2021169500A5 (cg-RX-API-DMAC10.html)
JP2021063088A5 (cg-RX-API-DMAC10.html)
JP2024512425A5 (cg-RX-API-DMAC10.html)
JP2002508361A5 (cg-RX-API-DMAC10.html)
JP2021530453A5 (cg-RX-API-DMAC10.html)
JP2004538303A5 (cg-RX-API-DMAC10.html)
JP2006526590A5 (cg-RX-API-DMAC10.html)
JP2020510085A5 (cg-RX-API-DMAC10.html)
JP2012255026A5 (cg-RX-API-DMAC10.html)
JP2006526031A5 (cg-RX-API-DMAC10.html)
JP2002509139A5 (cg-RX-API-DMAC10.html)
JP2013537423A5 (cg-RX-API-DMAC10.html)
JP2007533722A5 (cg-RX-API-DMAC10.html)
JP2022033950A5 (cg-RX-API-DMAC10.html)
JP2012520883A5 (cg-RX-API-DMAC10.html)
JP2008531742A5 (cg-RX-API-DMAC10.html)
JP2007510619A5 (cg-RX-API-DMAC10.html)
JP2021529829A5 (cg-RX-API-DMAC10.html)
JP2025502064A5 (cg-RX-API-DMAC10.html)
JPWO2024181437A5 (cg-RX-API-DMAC10.html)
JP2008536931A5 (cg-RX-API-DMAC10.html)